Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable, in the opinion of the investigator~* CVC occlusion~* Able to have fluids infused at the volume necessary to instill study drug into the CVC~Exclusion Criteria:~* Able to have 3 mL of blood (patients weighing ≥ 10 kg) or 1 mL of blood (patients weighing \< 10 kg) withdrawn from the selected study CVC following patient repositioning~* Selected study CVC inserted \< 2 days prior to treatment~* Selected study CVC known to be dysfunctional for \> 7 days~* Selected study CVC implanted specifically for hemodialysis (HD)~* Use of a power injector on the selected study CVC during the study~* Evidence of mechanical, non-thrombotic occlusion of the selected study CVC (e.g., kink in the catheter or suture constricting the catheter)~* Previously treated in this study or any tenecteplase catheter clearance trial~* Use of any investigational drug or therapy within 28 days prior to treatment~* Use of a fibrinolytic agent (e.g., alteplase, tenecteplase, reteplase, or urokinase) within 24 hours prior to treatment~* Known to be pregnant or breastfeeding at screening~* CVC with known or suspected infection~* History of any intracranial hemorrhage, aneurysm, or arteriovenous malformation~* Use of heparin (unfractionated or low molecular weight) within 24 hours prior to treatment, except for use of intermittent or low-dose, continuous infusion of heparin to maintain catheter or vessel patency~* Use of warfarin within 7 days prior to treatment, except for low-dose warfarin used for prophylaxis~* Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to treatment~* At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or clinically significant right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard~* Known hypersensitivity to tenecteplase or any component of the formulation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Tenecteplase + Tenecteplase (PTT) (Type: PLACEBO_COMPARATOR): None
- Tenecteplase + Tenecteplase + Placebo (TTP) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).